59424-95-2

Basic information

• Product Name: 2-Butenoic acid, 4-methoxy-, methyl ester
• Synonyms: 2-Butenoic acid, 4-methoxy-, methyl ester;4-METHOXYBUT-2-ENOIC ACID METHYL ESTER
• CAS NO: 59424-95-2
• Molecular Formula: C₆H₁₀O₃
• Molecular Weight: 130.14
• Mol File: 59424-95-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Butenoic acid, 4-methoxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butenoic acid, 4-methoxy-, methyl ester(59424-95-2)
• EPA Substance Registry System: 2-Butenoic acid, 4-methoxy-, methyl ester(59424-95-2)

Safety Data

• Hazardous Substances Data: 59424-95-2(Hazardous Substances Data)

Upstream product

• 13169-06-7 3,4-dimethoxy-butyric acid methyl ester 
• 67-56-1 methanol 
• 1117-71-1 methyl 4-bromocrotonate 

Relevant articles and documents

Method for synthesizing 4-methylaminocrotonate

The invention discloses a technology for synthesizing 4-methylaminocrotonate. The technology comprises the specific steps that methyl 4-bromocrotonate, methyl alcohol and a catalyst are added into a sealed reactor, heating is performed to perform a reaction under the temperature of 65 DEG C or above, after raw materials react completely, a reaction solution is cooled, then filtering is performed,solid by-products are removed, a filtrate is concentrated, excessive methyl alcohol is recycled, the obtained concentrated solution crude product is subjected to reduced pressure distillation purification, and the 4-methylaminocrotonate with the high purity can be obtained; the technology is adopted for synthesizing 4-methylaminocrotonate, the raw material 4-bromocrotonate is completely converted,post-processing operation is simplified, the reaction yield is increased, and the production cost is remarkably lowered.

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS

This invention provides compounds of formula (1) wherein X is C3-7 cycloalkyl, pyridinyl, pyrimidinyl or phenyl ring optionally substituted as described in claim 1, R1, R3 and R4 are chosen from the groups listed in claim 1. R2 is chosen from various unsaturated acyl groups listed in claim 1, with certain compounds being disclaimed. Use as tyrosine kinase inhibitors for the treatment of cancer and certain kidney diseases such as polycystic kidney disease.